Actimab-A: Additional Phase I/II data

Additional data from 12 previously untreated AML patients >=60 in cohorts 1-3 of an open-label, U.S. Phase I/II trial showed that Actimab-A

Read the full 221 word article

How to gain access

Continue reading with a
two-week free trial.